

**From:** [REDACTED]  
**To:** [ETF SMB Board Feedback](#)  
**Subject:** Anti obesity medication  
**Date:** Friday, February 7, 2025 4:34:32 PM

---

**CAUTION: This email originated from outside the organization.  
Do not click links or open attachments unless you recognize the sender and know the content is safe.**

Obesity is a chronic disease that significantly impacts the quality of life and longevity of millions of people. The rise in obesity rates correlates strongly with associated dangerous and costly health conditions such as heart disease, stroke, diabetes, immobility, and cancer, all of which pose serious long-term health risks, and contribute to skyrocketing healthcare costs and reduced worker productivity, among other negative health and economic affects.

Neighboring states including Minnesota, Illinois, Indiana, and Michigan offer anti-obesity medication as a benefit to their public employees, as do numerous other states and the federal government covered plans. Wisconsin's own Medicaid program covers these medications for its beneficiaries, as do many private and self-funded employers.

Please consider covering this medications

Respectfully,  
Deanne Hauch Quirk